{"filing":{"accession_number":"0001100682-26-000115","cik":"0001100682","ticker":"CRL","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"crl-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1100682/000110068226000115/crl-20260805.htm"},"events":[{"id":24375,"run_id":22077,"accession_number":"0001100682-26-000115","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Charles River Laboratories issued a press release on August 5, 2026, disclosing second-quarter 2026 financial results including revenue of $1.00 billion, GAAP loss per share of $(0.03), and non-GAAP earnings per share of $3.02. The filing explicitly states the press release is attached as an exhibit and provides comprehensive quarterly results with segment breakdowns, guidance updates, and forward-looking statements—all hallmarks of a standard earnings release disclosure under Item 2.02.","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":24896,"accession_number":"0001100682-26-000115","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Charles River Laboratories issued a press release on August 5, 2026, disclosing second-quarter 2026 financial results including revenue of $1.00 billion, GAAP loss per share of $(0.03), and non-GAAP earnings per share of $3.02. The filing explicitly states the press release is attached as an exhibit and provides comprehensive quarterly results with segment breakdowns, guidance updates, and forward-looking statements—all hallmarks of a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:26:34.552079+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24896,"accession_number":"0001100682-26-000115","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Charles River Laboratories issued a press release on August 5, 2026, disclosing second-quarter 2026 financial results including revenue of $1.00 billion, GAAP loss per share of $(0.03), and non-GAAP earnings per share of $3.02. The filing explicitly states the press release is attached as an exhibit and provides comprehensive quarterly results with segment breakdowns, guidance updates, and forward-looking statements—all hallmarks of a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:26:34.552079+00:00","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","filing_date":"2026-08-05"}]}